Skip to content

Clinical observation on the treatment of Parkinson's disease with fatigue by three injections

Clinical observation on the treatment of Parkinson's disease with fatigue by three injections

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006777
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease fatigue

Interventions

Experimental group:acupuncture

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria of PD (refer to the "MDS: Clinical diagnostic criteria for Parkinson's Disease" revised by the International Movement Disorders Association in 2015); ? Male or female, aged 35-75 years; ? Total score of Fatigue Severity Rating Scale (FSS) /9 >4 ? Subjects should know the protocol and sign the informed consent.

Exclusion criteria

Exclusion criteria: ?Patients with serious other systemic diseases, such as immune system diseases, endocrine system diseases (such as pheochromocytoma, hyperthyroidism, etc.), respiratory system diseases, cardiovascular and cerebrovascular diseases, or liver and kidney insufficiency. (2) Clear can lead to Parkinson's syndrome or suspected symptoms related to other diseases, such as Parkinson's syndrome, senile tremor, etc. ?There was definite cerebellar ataxia or cerebellar eye movement abnormalities. ?There was definite loss of compound sensory cortex and motor apraxia or progressive aphasia. ?Downward vertical supranuclear gaze palsy or downward vertical saccade selective slowing. ?Parkinson-like symptoms that remain confined to the lower extremities three years after onset. ?Highly suspected behavioral variant frontotemporal dementia or primary progressive aphasia was diagnosed within 5 years of onset ?There was no significant therapeutic response to high-dose levodopa treatment. ?Patients with a clear history of mental illness or psychotic symptoms, such as depression, schizophrenia, etc. ?Have a history of substance abuse (such as alcohol, drugs, caffeine), sleeping pills or psychoactive drugs in the past six months. ?He or she participated in other clinical trials of drugs, acupuncture and moxibustion within one month before being enrolled in this study. ?Moxibushite.

Design outcomes

Primary

MeasureTime frame
Multidimensional Fatigue scale;

Secondary

MeasureTime frame
Fatigue Severity Rating Scale;Parkinson's Disease Sleep Scale;Quality of life questionnaire for Parkinson's patients;Parkinson's Disease Fatigue Scale;Unified Parkinson's Disease Rating Scale Part 1;

Countries

China

Contacts

Public ContactChen Yuanyuan
916958133@qq.com13322691897

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026